Noninfectious Posterior Uveitis

• FDA approval · 2026-03-11
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  The FDA approved a supplemental application for OZURDEX (dexamethasone intravitreal implant) submitted by Allergan, Inc.

• FDA approval · 2025-04-04
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for Retisert (fluocinolone acetonide) submitted by Bausch & Lomb.

• FDA approval · 2016-02-05
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  The FDA approved a supplemental application for Ozurdex (dexamethasone) by Allergan, authorizing an expanded indication for the product.

• FDA approval · 2015-03-30
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for RETISERT (fluocinolone acetonide) submitted by Bausch & Lomb Incorporated, related to the cortic…

• FDA approval · 2014-06-20
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for RETISERT (fluocinolone acetonide) submitted by Bausch & Lomb Incorporated. The action updates th…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2010-11-30
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for Retisert (fluocinolone acetonide) submitted by Bausch & Lomb Incorporated. The action approves a…

• FDA approval · 2007-10-30
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for RETISERT, the fluocinolone acetonide implant by Bausch & Lomb. This action pertains to an amendm…